Post Reply
41-60 of 2522
when can sell the rights?
**Summary:**
DISA Limited' s Board of Directors has decided **not to proceed** with the previously proposed **share consolidation** after evaluating current market conditions, the company&rsquo s strategic direction, and its ongoing **fundraising efforts via a rights issue with warrants**. The Board reserves the right to revisit share consolidation in the future, subject to shareholder approval. Shareholders are advised to exercise caution when trading the company&rsquo s shares and consult professional advisors if uncertain.
**Key Points:**
- Decision based on market conditions, strategy, and fundraising activities.
- Future share consolidation would require renewed shareholder approval.
- Investors urged to act prudently and seek expert advice.
(Referenced documents: Announcements dated 29 April 2024, 27 May 2024, and Circular dated 10 May 2024.)
looks like Covid-19 is coming back.?
Accumulation at 0.001 is in progress. This stock will rise if Covid-19 is back again like Medtecs.
Low risk as it is rock bottom price.
Low risk as it is rock bottom price.
**Summary:**
The Company aims to raise capital via a Proposed Rights Cum Warrants Issue to expand its Shared Savings Program (SSP), managed by subsidiary DiSa Digital Safety Ple. Ltd. The SSP integrates RFID and 3S Smart Barcode technologies to combat return fraud in the US retail sector, which saw $685 billion in merchandise returns (2024), including $103 billion in fraudulent claims.
**Key Points:**
1. **Challenges (2017&ndash 2022):** DiSa initially struggled with slow adoption of its 3S Smart Barcodes due to the absence of retailer mandates and vendor cost burdens.
2. **RFID Mandate Shift (2022):** Major US retailers required RFID tags, improving inventory accuracy and operational efficiency. DiSa leveraged this by partnering with RFID manufacturers to integrate 3S Smart Barcodes into RFID tags, aligning with compliance needs.
3. **Revised SSP Model:**
- Provides 3S Smart Barcodes **free** to RFID manufacturers (not vendors), eliminating upfront costs.
- DiSa receives a share of retailers' savings from prevented fraud, based on a pre-agreed percentage of intercepted item values.
4. **Capital Use:** Funds will scale the SSP rollout, enhancing fraud prevention, growth, and operational efficiency through this dual-technology solution.
This strategic pivot addresses prior adoption barriers and capitalizes on existing RFID infrastructure to drive broader implementation.
Right money will feed the CEO and directors for few more years for losing monies year after year
Sold down indeed but buyers did come back at $0.001 .
The board of directors (the &ldquo Board&rdquo or &ldquo Directors&rdquo ) of the DISA Limited (the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ) wishes to announce that the Company proposes to undertake a non-renounceable non-underwritten rights cum warrants issue (&ldquo Proposed Rights Cum Warrants Issue&rdquo ) of:
(a) up to 4,510,123,361 new ordinary shares in the capital of the Company (the &ldquo Rights Shares&rdquo ) at an issue price of S$0.001 (&ldquo Issue Price&rdquo ) per Rights Share on the basis of two (2) Right Shares for every five (5) existing ordinary shares in the share capital of the Company (&ldquo Shares&rdquo ) held by the Entitled Shareholders (as defined below) as at a date and time to be determined by the Directors (the &ldquo Record Date&rdquo ), fractional entitlements to be disregarded and
(b) up to 4,510,123,361 free detachable and transferable warrants in the capital of the Company (&ldquo Warrants&rdquo ), each Warrant carrying the right to subscribe for one (1) new ordinary share in the share capital of the Company (&ldquo Warrant Share&rdquo ) at the exercise prices of S$0.005 and S$0.010 respectively for each Warrant Share, depending on the exercise periods within which the Warrants are exercised (further details of which are set out at paragraph 2 below) (&ldquo Exercise Prices&rdquo , and each an &ldquo Exercise Price&rdquo ), on the basis of one (1) Warrant for every one (1) Rights Share subscribed.
(a) up to 4,510,123,361 new ordinary shares in the capital of the Company (the &ldquo Rights Shares&rdquo ) at an issue price of S$0.001 (&ldquo Issue Price&rdquo ) per Rights Share on the basis of two (2) Right Shares for every five (5) existing ordinary shares in the share capital of the Company (&ldquo Shares&rdquo ) held by the Entitled Shareholders (as defined below) as at a date and time to be determined by the Directors (the &ldquo Record Date&rdquo ), fractional entitlements to be disregarded and
(b) up to 4,510,123,361 free detachable and transferable warrants in the capital of the Company (&ldquo Warrants&rdquo ), each Warrant carrying the right to subscribe for one (1) new ordinary share in the share capital of the Company (&ldquo Warrant Share&rdquo ) at the exercise prices of S$0.005 and S$0.010 respectively for each Warrant Share, depending on the exercise periods within which the Warrants are exercised (further details of which are set out at paragraph 2 below) (&ldquo Exercise Prices&rdquo , and each an &ldquo Exercise Price&rdquo ), on the basis of one (1) Warrant for every one (1) Rights Share subscribed.
Disa Cheong today...don't miss..dyodd
Disa wins contract for clinical deployment of Automated Visual Acuity Test at major Singapore hospital
Digital Life Line (DLL), a wholly-owned subsidiary of Disa, has been awarded a letter of award from one of Singapore' s major public hospitals. The group has also signed the letter of acknowledgement and the relevant contract for the clinical deployment of its automated visual acuity test (AVAT) devices at a hospital ophthalmology clinic in Singapore from Feb 3 this year to Feb 2, 2026.
Under the contract, DLL will supply AVAT on a leasing basis, charging a fixed monthly rental fee along with a per-test fee, creating a hybrid pricing structure. This approach ensures a steady revenue stream through the fixed rental while allowing for scalability based on usage
This milestone follows a two-month-long pilot study at the Department of Ophthalmology of a public hospital that assesses the accuracy, usability and patient satisfaction of AVAT, and the AVAT is the result of several years of dedicated research and development work by the Department of Ophthalmology at the National University Hospital and Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore.
This marks the first commercial deployment of AVAT in Singapore, and the group received Class A Medical Device Registration for AVAT from the Health Science Authority (HSA) Singapore in August 2023.
Eddie Chng, managing director and CEO, DLL, says: &ldquo We are truly honoured to be given the opportunity to deploy AVAT in Singapore. Due to the convenience and reduced manpower needs, self-administered kiosks are becoming common, ranging from supermarket self-checkout machines to home-based blood pressure monitoring devices.&rdquo
&ldquo We know that loss of eyesight is irreversible, so the widespread deployment of devices like AVAT in the community is key not only for early diagnosis and intervention, but also to alleviate the workload at tertiary hospitals facing severe manpower shortages,&rdquo concludes Chng.
.looks like no interest now, volume dropped 😴
bernardc ( Date: 14-Jan-2025 09:22) Posted:
|
Recently there is a rights issue for one of disa subsidiary..
Not Disa..
For DIGITAL LIFESTYLE...
mattohoh ( Date: 13-Jan-2025 19:33) Posted:
|
This news is placement ah? At what price eh
tonytony ( Date: 13-Jan-2025 19:28) Posted:
|
There were about 45m cash after few round of fund raising 5 years ago . ， Just one question , where are all the monies ? Both brothers did nothing but draw millions and millions of incomes year after year.
mattohoh ( Date: 13-Jan-2025 19:21) Posted:
|
This one will affect share price anot? Raise at what price
tonytony ( Date: 13-Jan-2025 19:19) Posted:
|
Raise monies again , cancel this later , monies raised can pay both brothers few more years of salaries and perks
mattohoh ( Date: 13-Jan-2025 19:17) Posted:
|
Can someone tell me what does this means is good or bad
mattohoh ( Date: 13-Jan-2025 19:17) Posted:
|
https://links.sgx.com/FileOpen/Disa%20-%20Signing%20of%20Term%20Sheet_RA_13Jan25.ashx?App=Announcement&FileID=830334
bernardc ( Date: 09-Jan-2025 14:28) Posted:
|
Hoot argh
...hoot..hoot
Disa subsidiary signs licensing agreement with NUH and NUS to commercialise cataract diagnostic device
Digital Life Line Pte. Ltd., a subsidiary of DiSa Digital Safety Pte. Ltd., has signed a tri-party licensing agreement with the National University Hospital (Singapore) or NUH and the National University of Singapore (NUS) to commercialise the company&rsquo s mobile imaging device for anterior segment (MIDAS) on Jan 7. DiSa Digital Safety Pte. Ltd. is a wholly-owned subsidiary of Catalist-listed Disa Limited.
In its business update on Oct 25, 2024, Disa said that it was focusing on its eye screening devices, which included the development of MIDAS, which could detect eye pathologies. MIDAS, a portable smartphone slit lamp imaging device, is registered with the Health Science Authority of Singapore (HSA) and is designed for cataract screening in primary care settings. The device is meant to be used by patients, nurses, primary care physicians such as general practitioners, polyclinic doctors and emergency physicians.
According to Disa, chronic eye conditions such as cataracts are becoming increasingly common among Singapore&rsquo s rapidly ageing population. Referring to a study conducted by the Singapore National Eye Centre, over 80% of people aged 60 and above in Singapore have some form of cataract.
&ldquo We are honoured to be given another opportunity to work with NUH and NUS to commercialise MIDAS in Singapore and hopefully, regionally in the near future,&rdquo says Eddie Chng, managing director and CEO of Disa and Digital Life Line.
&ldquo With our portable artificial intelligence-powered cataract screening device, we are bringing advanced eye care directly to the community,&rdquo he adds. &ldquo Our in-house developed artificial intelligence (AI)-algorithms can eliminate the need for trained staff to identify the best image and process the cataract grading parameters within 10 seconds. By harnessing intelligent triaging based on an established cataract grading system, we aim to ensure that each referral is both timely and accurate.&rdquo